Skip to content
Screener

iRadimed IRMD Q2 2025 earnings

Reported August 1, 2025 · Before market open

Revenue$20.4MMiss by $89.1K
EPS$0.49Beat by $0.04
Revenue estimate$20.5M
EPS estimate$0.45

Next report

Nov 2, 2026 (in a month)
Revenue estimate$23.2M
EPS estimate$0.52

Financials

Q2 2025

Income statement

See full
Revenue$20.4M+13.8%
Gross profit$16.0M+13.9%
Operating income$6.8M+20.6%
Net income$5.8M+17.8%
EPS (diluted)$0.45+18.4%

Balance sheet

See full
Cash & equivalents$53.0M+9.2%
Total equity$94.3M+18.4%
Total assets$106.4M+18.3%

Cash flow

See full
Operating cash flow$7.7M+16.7%
CapEx$2.6M+132%
Free cash flow$5.1M-7.2%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$769.01M+38.2%
P/E37.2×+7.4×
P/S9.9×+1.9×

Profitability

See full
Gross margin77%-0.2pp
Operating margin30.7%-0.2pp
Net margin26.6%-0.2pp
FCF margin18.3%-1.2pp

Returns & leverage

See full
Return on equity23.7%-1.3pp
Current ratio8.8×-1.1×

FAQ

When did iRadimed report Q2 2025 earnings?
iRadimed (IRMD) reported Q2 2025 earnings on August 1, 2025 before market open.
What were iRadimed's Q2 2025 revenue and EPS?
iRadimed reported revenue of $20.4M and eps of $0.49 for Q2 2025.
Did iRadimed beat estimates in Q2 2025?
Revenue missed the consensus estimate of $20.5M by $89.1K. EPS beat the consensus estimate of $0.45 by $0.04.
How did iRadimed's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 13.8% from $17.9M a year earlier and eps grew 16.7% from $0.42.
Where can I find iRadimed's Q2 2025 SEC filings?
You can read the 8-K earnings release (0001558370-25-009933) and the 10-Q periodic report (0001558370-25-009987) directly on SEC EDGAR. The filing index links above go to sec.gov.